Literature DB >> 33033149

Long-term prognosis of new adult-onset asthma in obese patients.

Pinja Ilmarinen1, Adrienn Pardo2, Leena E Tuomisto2, Iida Vähätalo2, Onni Niemelä3,4, Pentti Nieminen5, Hannu Kankaanranta2,4,6.   

Abstract

BACKGROUND: Obesity has been associated with poor outcomes of asthma in cross-sectional studies, but long-term effect of obesity on asthma remains unknown. AIMS: To study the effects of obesity, found at the time of diagnosis of adult-onset asthma, on 12-year prognosis by focusing on oral corticosteroid (OCS) use and respiratory-related hospital admissions.
METHODS: Patients diagnosed with adult-onset asthma (n=203) were divided into three categories based on diagnostic body mass index (BMI) (<25 kg·m-2, 25-29.9 kg·m-2, ≥30 kg·m-2) and followed for 12 years as part of the Seinäjoki Adult Asthma Study. Self-reported and dispensed OCS were assessed for the 12-year period. Data on hospital admissions were analysed based on medical records.
RESULTS: 12 years after diagnosis, 86% of the patients who were obese (BMI ≥30 kg·m-2) at diagnosis remained obese. During the follow-up, no difference was found in weight gain between the BMI categories. During the 12-year follow-up, patients obese at diagnosis reported more frequent use of OCS courses (46.9% versus 23.1%, p=0.028), were dispensed OCS more often (81.6% versus 56.9%, p=0.014) and at higher doses (median 1350 (interquartile range 280-3180) mg versus 600 (0-1650) mg prednisolone, p=0.010) compared to normal-weight patients. Furthermore, patients who were obese had more often one or more respiratory-related hospitalisations compared to normal-weight patients (38.8% versus 16.9%, p=0.033). In multivariate logistic regression analyses, obesity predicted OCS use and hospital admissions.
CONCLUSIONS: In adult-onset asthma, patients obese at diagnosis mostly remained obese at long-term and had more exacerbations and respiratory-related hospital admissions compared to normal-weight patients during 12-year follow-up. Weight loss should be a priority in their treatment to prevent this outcome.
Copyright ©ERS 2021.

Entities:  

Year:  2021        PMID: 33033149     DOI: 10.1183/13993003.01209-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  2 in total

1.  STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life.

Authors:  Jasper H Kappen; Elisabeth F C van Rossum; Jan A Witte; Gert-Jan Braunstahl; Wouter J B Blox; Susan C van 't Westeinde; Johannes C C M In 't Veen
Journal:  BMC Pulm Med       Date:  2022-02-05       Impact factor: 3.317

2.  Determinants of Severe Asthma - A Long-Term Cohort Study in Northern Sweden.

Authors:  Helena Backman; Caroline Stridsman; Linnea Hedman; Lina Rönnebjerg; Bright I Nwaru; Thomas Sandström; Hannu Kankaanranta; Anne Lindberg; Eva Rönmark
Journal:  J Asthma Allergy       Date:  2022-10-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.